Cap Insulin Prices Act

Issues related to Direct-to-Consumer Prescription Drug Advertisements; Issues related to Cybersecurity; Health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act 2024; Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023; Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; Issues related to P.L. 93-406, Employee Retirement Income Security Act of 1974 (ERISA), preemption; S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; H.R. 1485, Insulin for all Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; S. 464/ H.R. 2630, the Safe Step Act; H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023; H.R. 1843/S. 1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; Issues related to mental health coverage, workforce, and mental health parity; Issues related to surprise billing law and regulation; Issues related to artificial intelligence and health care issues; Issues related to removing barriers to biosimilar medicine access; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; H.R. 3432/S.3651, Telemental Health Care Access Act of 2023; H.R. 1692, The Health Care Affordability Act; H.R. 8152, the American Privacy Rights Act (APRA) of 2024.

Client expense: $2,200,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to Direct-to-Consumer Prescription Drug Advertisements; Issues related to Cybersecurity; Health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act 2024; Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023; Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; Issues related to P.L. 93-406, Employee Retirement Income Security Act of 1974 (ERISA), preemption; S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023; S. 5093, Behavioral Health Network and Directory Improvement Act; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; S. 464/ H.R. 2630, the Safe Step Act; H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023; H.R. 1843/S. 1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; S. 3393 Support for Patients and Communities Reauthorization Act; Issues related to mental health coverage, workforce, and mental health parity; Issues related to surprise billing law and regulation; Issues related to artificial intelligence and health care issues; Issues related to removing barriers to biosimilar medicine access; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; H.R. 3432/S.3651, Telemental Health Care Access Act of 2023.

Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program

Client expense: Not reported · Firm income: $90,000

Issues related to surprise billing law and regulation; Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations; Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; Issues related to removing barriers to biosimilar medicine access; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program; Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023; Issues related to mental health coverage, workforce, and mental health parity. S. 5093, Behavioral Health Network and Directory Improvement Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; Issues relating to S. 464/ H.R. 2630, the Safe Step Act; related amendment to S. 1339, the Pharmacy Benefit Manager Reform Act; H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023; S. 2840, Bipartisan Primary Care and Health Workforce Act and issues related commercial insurance, telehealth, and pharmacy benefits; H.R. 1843/S. 1001, the Telehealth Expansion Act of 2023 and related issues; S. 3393 Support for Patients and Communities Reauthorization Act; Issues related to artificial intelligence and health care issues; Issues related to P.L. 93-406, Employee Retirement Income Security Act of 1974 (ERISA), preemption.

Issues related to surprise billing law and regulation. Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. Issues related to removing barriers to biosimilar medicine access. Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program. Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023. Issues related to mental health coverage, workforce, and mental health parity. Behavioral Health Network and Directory Improvement Act. S. 1001, Issues related to the Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 1843, the Telehealth Expansion Act of 2023. H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues relating to S. 464/ H.R. 2630, the Safe Step Act; related amendment to S. 1339, the Pharmacy Benefit Manager Reform Act. H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023. S. 2840, Bipartisan Primary Care and Health Workforce Act and issues related commercial insurance, telehealth, and pharmacy benefits.

Legislative and administrative monitoring and outreach on healthcare policy. Legislative and administrative monitoring and outreach on prescription drug pricing/PBMs. Legislative and administrative monitoring and outreach on policy issues affecting Medicaid programs. H.R. 134, To amend title XVIII of the Social Security Act to remove geographic requirements and expand originating sites for telehealth services. H.R. 197, Rural Telehealth Expansion Act H.R. 198, Drug Pricing Transparency and Accountability Act H.R. 207, Advanced Safe Testing at Residence Telehealth Act of 2023 H.R. 497, Freedom for Health Care Workers Act H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023 H.R. 1066, CARING for Social Determinants Act of 2023 H.R. 1215, Healthcare Worker Retention Act H.R. 1488, Affordable Insulin Now Act H.R. 1587, Making Insulin Affordable for All Children Act H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 1843, Telehealth Expansion Act of 2023 H.R. 2534, To amend title XXVII of the Public Health Service Act to ensure the equitable treatment of covered entities and pharmacies participating in the 340B drug discount program, and for other purposes. S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 146, Cap Insulin Prices Act S. 710, Striking and Locked Out Workers Healthcare Protection Act S. 729, Audio-Only Telehealth for Emergencies Act S. 731, TELEHEALTH HSA Act of 2023 S. 880, Coordinating Dual Eligible Recommendations Act S. 1001, A bill to amend the Internal Revenue Code of 1986 to permanently extend the exemption for telehealth services from certain high deductible health plan rules. S.113, Prescription pricing for the People Act S.1339, Pharmacy Benefit Manager Reform Act H.R. 3284, Providers and Payers Compete Act H.R. 3561, Patient Act S. 880, Coordinating Dual Eligible Recommendations Act H.R. 4697, Protecting PAHPA Act S.2624, Labor-HHS-Education Appropriations Act H.R. 5378, Lower Costs, More Transparency ActPrice Transparency H.R. 4368, Agriculture Appropriations Act S. 2131, Agriculture Appropriations Act H.R. 5860, Continuing Appropriations Act

Educate policymakers on pharmacy issues related to TRICARE and H.R.2670, S.2226 Fiscal Year 2024 National Defense Authorization Act; issues related to P.L 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations; issues related to P.L 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; issues related to removing barriers to biosimilar medicine access; issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, INSULIN Act of 2023; S. 146, Cap Insulin Prices Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; issues related to mental health coverage, workforce, and mental health parity and the Behavioral Health Network and Directory Improvement Act and S. 2840, Bipartisan Primary Care and Health Workforce Act; and issues related commercial insurance, telehealth, and pharmacy benefits.

Client expense: Not reported · Firm income: $90,000

Issues related to surprise billing law and regulation. Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. Issues related to removing barriers to biosimilar medicine access. Issues related to Quality-Adjusted Life Year (QALY) or similar metrics in health coverage legislation. Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program. Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S. 1542, the Delinking Revenue from Unfair Gouging Act (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, the PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. H.R. 2813, Self-Insurance Protection Act. Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S. 954, Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; H.R. 1485, Insulin for all Act of 2023. Issues related to mental health coverage, workforce, and mental health parity. Behavioral Health Network and Directory Improvement Act. S. 1001, Issues related to the Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 1843, the Telehealth Expansion Act of 2023. H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues relating to H.R. 3799, Custom Health Option and Individual Care Expense Arrangement Act (the CHOICE Arrangement Act). Issues relating to S. 464 / H.R. 2630, the Safe Step Act; related amendment to S. 1339.

Legislative and administrative monitoring and outreach on healthcare policy. Legislative and administrative monitoring and outreach on prescription drug pricing/PBMs. Legislative and administrative monitoring and outreach on policy issues affecting Medicaid programs. H.R. 134, To amend title XVIII of the Social Security Act to remove geographic requirements and expand originating sites for telehealth services. H.R. 197, Rural Telehealth Expansion Act H.R. 198, Drug Pricing Transparency and Accountability Act H.R. 207, Advanced Safe Testing at Residence Telehealth Act of 2023 H.R. 497, Freedom for Health Care Workers Act H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023 H.R. 1066, CARING for Social Determinants Act of 2023 H.R. 1215, Healthcare Worker Retention Act H.R. 1488, Affordable Insulin Now Act H.R. 1587, Making Insulin Affordable for All Children Act H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 1843, Telehealth Expansion Act of 2023 H.R. 2534, To amend title XXVII of the Public Health Service Act to ensure the equitable treatment of covered entities and pharmacies participating in the 340B drug discount program, and for other purposes. S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 146, Cap Insulin Prices Act S. 710, Striking and Locked Out Workers Healthcare Protection Act S. 729, Audio-Only Telehealth for Emergencies Act S. 731, TELEHEALTH HSA Act of 2023 S. 880, Coordinating Dual Eligible Recommendations Act S. 1001, A bill to amend the Internal Revenue Code of 1986 to permanently extend the exemption for telehealth services from certain high deductible health plan rules. S.113, Prescription pricing for the People Act S.1339, Pharmacy Benefit Manager Reform Act H.R. 3284, Providers and Payers Compete Act H.R. 3561, Patient Act H.R. 3746, Fiscal Responsibility Act S. 880, Coordinating Dual Eligible Recommendations Act

Issues related to prescription drug pricing, particularly as it relates to insulin S. 146 - Cap Insulin Prices Act HR 1488/S. 954 - Affordable Insulin Now Act H.R. 1485 - Insulin for All Act of 2023 H.R.1587 - Making Insulin Affordable for All Children Act Issues related to the Special Diabetes Program renewal

Client expense: $330,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislative and administrative monitoring and outreach on healthcare policy. Legislative and administrative monitoring and outreach on prescription drug pricing/PBMs. Legislative and administrative monitoring and outreach on policy issues affecting Medicaid programs. H.R. 134, To amend title XVIII of the Social Security Act to remove geographic requirements and expand originating sites for telehealth services. H.R. 197, Rural Telehealth Expansion Act H.R. 198, Drug Pricing Transparency and Accountability Act H.R. 207, Advanced Safe Testing at Residence Telehealth Act of 2023 H.R. 497, Freedom for Health Care Workers Act H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023 H.R. 1066, CARING for Social Determinants Act of 2023 H.R. 1215, Healthcare Worker Retention Act H.R. 1488, Affordable Insulin Now Act H.R. 1587, Making Insulin Affordable for All Children Act H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 1843, Telehealth Expansion Act of 2023 H.R. 2534, To amend title XXVII of the Public Health Service Act to ensure the equitable treatment of covered entities and pharmacies participating in the 340B drug discount program, and for other purposes. S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 146, Cap Insulin Prices Act S. 710, Striking and Locked Out Workers Healthcare Protection Act S. 729, Audio-Only Telehealth for Emergencies Act S. 731, TELEHEALTH HSA Act of 2023 S. 880, Coordinating Dual Eligible Recommendations Act S. 1001, A bill to amend the Internal Revenue Code of 1986 to permanently extend the exemption for telehealth services from certain high deductible health plan rules.

Client expense: Not reported · Firm income: $30,000

Affordable Care Act, Extending ARPA Subsidies, Individual Market Reform, Behavioral Health (S. 923), Health Equity, Maternal Health, Implementation of No Surprises Act, Health IT, Interoperability, Value-Based Care, Health Care Innovation, COVID-19 PHE Transition (Medicaid Redeterminations, Commercialization of COVID-19 Vaccines & Therapeutics), HIPAA and Privacy, Telehealth, Public Option, Pharmacy Benefit Managers (S. 113, S. 127), Insulin Affordability (S. 146, S. 954, S. 727, H.R. 1485), Transparency (H.R. 410, S. 1130), Affordability (site neutral payment policies)

Client expense: $590,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE